SCHEMBL3315348

SCHEMBL3315348

COc1cc(N2CCCC2C(=O)N2CCOCC2)ccc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 1/20 0.42
KMT2A Q03164 2/20 0.42
TSHR P16473 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAK O14976 1/20 0.41
POLB P06746 1/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
CDC42BPB Q9Y5S2 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GLA P06280 1/20 0.40
AKR1C3 P42330 1/20 0.39
PIK3CA P42336 1/20 0.39
CHEK1 O14757 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3312862 0.84 ALDH1A1 (0.53) ALDH1A1KDM4EKMT2AMEN1LMNA
SCHEMBL15938452 0.83 PIK3CA (0.46) ALDH1A1SMN1; SMN2PIK3CA
SCHEMBL15937995 0.83 PIK3CA (0.46) ALDH1A1SMN1; SMN2PIK3CA
SCHEMBL15937994 0.83 PIK3CA (0.46) ALDH1A1SMN1; SMN2PIK3CA
SCHEMBL13178107 0.81 ALDH1A1 (0.53) ALDH1A1KDM4EKMT2AMEN1LMNA
SCHEMBL20156021 0.76 ALDH1A1 (0.41) ALDH1A1TSHRCYP3A4HTT
SCHEMBL13362137 0.75 AKR1C3 (0.66) ALDH1A1LMNAAKR1C3CHEK1
SCHEMBL29779476 0.74 AKR1C3 (0.54) ALDH1A1KMT2ATSHRMEN1L3MBTL1
SCHEMBL12714776 0.74 HTR4 (0.47) KMT2AMEN1POLBSMN1; SMN2
SCHEMBL12714777 0.74 HTR4 (0.47) KMT2AMEN1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105655-A1 NOVEL COMPOUNDS 515 ASTRAZENECA AB 2010-04-29 US disclosed
US-20100105655-A1 NOVEL COMPOUNDS 515 ASTRAZENECA AB 2010-04-29 US disclosed
US-20100105655-A1 NOVEL COMPOUNDS 515 ASTRAZENECA AB 2010-04-29 US disclosed
US-20100105767-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105767-A1 COMPOUNDS, COMPOSITIONS AND METHODS ALPP, PCNA, MKI67 ALDH1A1 2715/4885KDM4E 1983/4885KMT2A 2046/4885
US-20100105655-A1 NOVEL COMPOUNDS 515 TYMS, ABCG2, UMPS ALDH1A1 649/4885KDM4E 2169/4885KMT2A 3784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.